

Reference:	FOI.4313.20
Subject:	Head and neck and renal cancer
Date of Request:	19 October 2020

Requested:

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma)? Of these patients, how many are locally advanced, recurrent and/or metastatic?
 - Total squamous cell carcinoma
 - Locally advanced
 - Recurrent and/or metastatic

2. For the metastatic head and neck cancer patients treated in the past 3 months, could you specify (if possible) how many received first-line treatment versus second-line treatment?

3. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
 - Carboplatin (monotherapy or in combination with 5-FU)
 - Cisplatin (monotherapy or in combination with 5-FU)
 - Cetuximab with/without chemotherapy
 - Cetuximab with radiotherapy
 - Pembrolizumab monotherapy
 - Pembrolizumab with chemotherapy
 - Nivolumab
 - Docetaxel (monotherapy or in combination with 5-FU)
 - Fluorouracil (5FU)
 - Radiotherapy only
 - Other

4. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
 - Sunitinib
 - Avelumab + Axitinib
 - Axitinib
 - Cabozantinib
 - Everolimus
 - Lenvantinib + Everolimus
 - Nivolumab
 - Nivolumab + Ipilimumab
 - Pazopanib
 - Pembrolizumab + Axitinib
 - Sunitinib
 - Temsirolimus
 - Tivozanib
 - Other

5. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
6. Does your trust participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part?

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare team, who hold a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records to establish the type of cancer diagnosed and therapies used to treat the patients. It is estimated that conducting this search would take longer than the 18 hour ‘appropriate limit’ as stated within the Act.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act, the UHB has an obligation to provide advice and assistance.

We would therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB who may be able to help you with your enquiry: -

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.